6,793 results on '"Karakiewicz, Pierre, I"'
Search Results
202. Metabolic Syndrome Predicts Worse Perioperative Outcomes in Patients Treated With Partial Nephrectomy for Renal Cell Carcinoma
203. Complication rates, failure to rescue and in-hospital mortality after cytoreductive nephrectomy in the older patients
204. The prognostic value of the urokinase-plasminogen activator system (uPA) in bladder cancer patients treated with radical cystectomy (RC)
205. Effect of stage and grade migration on cancer specific mortality in renal cell carcinoma patients, according to clear cell vs. non-clear cell histology: A contemporary population-based analysis
206. Histotype predicts the rate of lymph node invasion at nephrectomy in patients with nonmetastatic renal cell carcinoma
207. The impact of very high initial PSA on oncological outcomes after radical prostatectomy for clinically localized prostate cancer
208. Survival After Partial Cystectomy for Variant Histology Bladder Cancer Compared With Urothelial Carcinoma: A Population-based Study
209. Partial Cystectomy With Pelvic Lymph Node Dissection for Patients With Nonmetastatic Stage pT2-T3 Urothelial Carcinoma of Urinary Bladder: Temporal Trends and Survival Outcomes
210. Impact of Patients’ Gender on Efficacy of Immunotherapy in Patients With Metastatic Kidney Cancer: A Systematic Review and Meta-analysis
211. Definition of high-risk prostate cancer impacts oncological outcomes after radical prostatectomy
212. Improved Survival in Contemporary Community-Based Patients With Metastatic Clear-Cell Renal Cell Carcinoma Undergoing Active Treatment
213. Access to trimodal therapy in muscle-invasive bladder cancer is lower in unmarried females
214. Preoperative plasma insulin-like growth factor-I and its binding proteins-based risk stratification of patients treated with radical nephroureterectomy for upper tract urothelial carcinoma
215. PD23-06 SURVIVAL DIFFERENCES BETWEEN PHEOCHROMOCYTOMA AND PARAGANGLIOMA PATIENTS
216. PD23-09 THE EFFECT OF ADRENALECTOMY ON OVERALL SURVIVAL IN METASTATIC ADRENOCORTICAL CARCINOMA
217. MP14-10 IDENTIFYING THE OPTIMAL CANDIDATE FOR CONCOMITANT ANDROGEN-DEPRIVATION THERAPY AMONG PATIENTS RECEIVING METASTASIS-DIRECTED THERAPY FOR POSITIVE PSMA PET AND PRIMARY OR SECONDARY BIOCHEMICAL RECURRENCE FROM PROSTATE CANCER
218. MP14-13 EXPLORING THE INTERACTION BETWEEN THE USE OF METASTASIS DIRECTED THERAPY IN PATIENTS WITH POSITIVE PSMA PET AND PATTERNS OF BIOCHEMICAL RECURRENCE AFTER RADICAL PROSTATECTOMY. RESULTS OF A LARGE, SINGLE INSTITUTION SERIES
219. PD23-07 PROGNOSTIC SIGNIFICANCE OF LYMPH NODE COUNT IN SURGICALLY TREATED PATIENTS WITH T 2-4 STAGE NON-METASTATIC ADRENOCORTICAL CARCINOMA
220. MP01-01 INCREMENTAL DOSE-RESPONSE EFFECT OF AGE ON MORTALITY IN NON-SEMINOMA TESTIS CANCER PATIENTS
221. MP14-11 THE ADDED VALUE OF CONCOMITANT WHOLE-PELVIS SALVAGE RADIATION THERAPY IN OLIGO-RECURRENT PROSTATE CANCER PATIENTS TREATED WITH METASTASIS-DIRECTED THERAPY FOR DISTANT POSITIVE UPTAKES AT PSMA PET
222. MP38-16 SURVIVAL BENEFIT OF NEPHROURETERECTOMY IN SYSTEMIC THERAPY EXPOSED METASTATIC UPPER TRACT URINARY UROTHELIAL CARCINOMA PATIENTS
223. MP22-07 CONTEMPORARY CONDITIONAL CANCER-SPECIFIC SURVIVAL RATES IN SURGICALLY TREATED NON-METASTATIC PRIMARY URETHRAL CARCINOMA
224. Temporal trends and cancer-specific mortality in non-metastatic muscle-invasive urothelial carcinoma of the urinary bladder treated with trimodal therapy
225. MP37-20 THE EFFECT OF PENILE REHABILITATION AFTER ROBOT-ASSISTED RADICAL PROSTATECTOMY ON URINARY CONTINENCE AND ERECTILE FUNCTION RECOVERY. RESULTS FROM a HIGH-VOLUME, SINGLE-SURGEON SERIES
226. First‐line immunotherapy of metastatic renal cell carcinoma: an updated network meta‐analysis including triplet therapy
227. Contemporary conditional cancer‐specific survival rates in surgically treated nonmetastatic primary urethral carcinoma
228. Racial and ethnic differences in survival in contemporary metastatic renal cell carcinoma patients, according to alternative treatment modalities
229. The effect of age on cancer-specific mortality in patients with prostate cancer : a population-based study across all stages
230. Association of De Ritis ratio with oncological outcomes in patients with non-muscle invasive bladder cancer (NMIBC)
231. Detectable Prostate-specific antigen value between 0.01 and 0.1 ng/ml following robotic-assisted radical prostatectomy (RARP): does it correlate with future biochemical recurrence?
232. The impact of sex and age on distribution of metastases in patients with renal cell carcinoma
233. Holmium laser enucleation of the prostate: efficacy, safety and preoperative management in patients presenting with anticoagulation therapy
234. Cancer-Specific Mortality Differences in Specimen-Confined Radical Prostatectomy Patients According to Lymph Node Invasion
235. Conditional survival of stage III non-seminoma testis cancer patients
236. Patient frailty predicts worse perioperative outcomes and higher cost after radical cystectomy
237. Increasing Rates of Perioperative Chemotherapy are Associated With Improved Survival in Men With Urothelial Bladder Cancer With Prostatic Stromal Invasion
238. Adenocarcinoma of the Bladder: Assessment of Survival Advantage Associated With Radical Cystectomy and Comparison With Urothelial Bladder Cancer
239. Conditional survival of patients with low-risk prostate cancer: Temporal changes in active surveillance permanence over time
240. Molecular biomarkers to help select neoadjuvant systemic therapy for urothelial carcinoma of the bladder
241. Radical cystectomy plus chemotherapy in patients with pure squamous cell bladder carcinoma: a population-based study
242. External beam radiation therapy improves survival in low-volume metastatic prostate cancer patients: a North American population-based study
243. Association of neurovascular bundle preservation with oncological outcomes in patients with high-risk prostate cancer
244. PSA, stage, grade and prostate cancer specific mortality in Asian American patients relative to Caucasians according to the United States Census Bureau race definitions
245. Prognostic factors in patients with small renal masses: a comparison between <2 vs. 2.1–4 cm renal cell carcinomas
246. Systemic therapy for metastatic renal cell carcinoma in the first-line setting: a systematic review and network meta-analysis
247. Comparison of survival outcomes in patients with metastatic papillary vs. clear-cell renal cell carcinoma: a propensity-score analysis
248. Combined systematic versus stand-alone multiparametric MRI-guided targeted fusion biopsy: nomogram prediction of non-organ-confined prostate cancer
249. Sequential therapy of abiraterone and enzalutamide in castration-resistant prostate cancer: a systematic review and meta-analysis
250. Preoperative frailty predicts adverse short-term postoperative outcomes in patients treated with radical prostatectomy
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.